Stocksigma LogoStocksigma Logo

Evonile Pharma Approves Rights Issue to Raise Up to ₹9,000 Million

The Board of Directors of Evonile Pharma Limited (formerly Novartis India Limited) approved raising up to ₹9,000 million through a rights issue of partly

Evonile Pharma Approves Rights Issue to Raise Up to ₹9,000 Million

Novartis India Ltd · Others (Uncategorized) · 09 Oct 2026, 12:40 am

Evonile Pharma Approves Rights Issue to Raise Up to ₹9,000 Million The Board of Directors of Evonile Pharma Limited (formerly Novartis India Limited) approved raising up to ₹9,000 million through a rights issue of partly paid-up equity shares with a face value of ₹5 each at its meeting on 8th Oct'26. The board constituted a Rights Issue Committee to finalize the issue terms, price, entitlement ratio, and record date. The fundraising remains subject to shareholder approval via postal ballot and statutory clearances. Additionally, the company launched its new corporate website under the name Evonile Pharma.

Original exchange filing (PDF)

More announcements from Novartis India Ltd

All Novartis India Ltd announcements